论文部分内容阅读
报告１１例急性双表型白血病（ＡＢＬ）的诱导化疗结果。５例ＡＢＬ经ＤＡＰＴＯ方案诱导化疗，４例于２８～５０天内完全缓解（ＣＲ）．持续ＣＲ时间７～１４月，存活时间８～１８月，１例仍无病生存。其余６例应用ＤＶＰ等方案化疗（Ｒ２例，持续ＣＲ分别为４和８月，６例患者除１例生存１６月外，余未超过７月。分析了ＡＢＬ的免疫表型、骨髓原始细胞减少指数（ＭＢＤＩ）与疗效的关系。认为探讨ＡＢＬ的治疗有重要意义，对ＡＢＬ患者应采用不同于ＡＭＬ或ＡＬＬ的化疗方案，用ＤＡＰＴＯ对ＡＢＬ进行诱导化疗似有较好疗效，值得进一步研究。
The results of induction chemotherapy for 11 cases of acute biphenotypic leukemia (ABL) were reported. Five patients with ABL received chemotherapy with DAPTO regimen, and 4 patients achieved complete remission (CR) within 28-50 days. The duration of CR was 7 to 14 months, and the survival time was from 8 to 18 months. 1 case was still disease-free. The remaining 6 patients were treated with chemotherapy such as DVP regimen (R2 patients, continuous CR were 4 and 8 months, 6 patients except 1 patient survived 16 months, and the rest did not exceed 7 months. The immunophenotype of ABL, bone marrow blasts were analyzed. The relationship between index (MBDI) and efficacy.It is considered that the treatment of ABL is of great significance. The chemotherapy regimen different from AML or ALL should be used for ABL patients. The induction chemotherapy with AAPTO for ABL seems to have better efficacy and worthy of further study.